Polatuzumab Vedotin-piiq and Somatropin, mammalian derived Subcutaneous, Injection
Determining the interaction of Polatuzumab Vedotin-piiq and Somatropin, mammalian derived Subcutaneous, Injection and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Consumer information for this interaction is not currently available.MONITOR: Coadministration with inducers of CYP450 3A4 may decrease exposure to unconjugated monomethyl auristatin E (MMAE), the anti-mitotic and cytotoxic component of polatuzumab vedotin. MMAE is a substrate for CYP450 3A4. Concomitant use of polatuzumab vedotin with rifampin, a potent CYP450 3A4 inducer, is predicted to decrease unconjugated MMAE exposure (AUC) by 63% according to the product labeling. No data are available for other, less potent CYP450 3A4 inducers. MANAGEMENT: The potential for diminished pharmacologic effects of polatuzumab vedotin should be considered during coadministration with CYP450 3A4 inducers. Alternative treatments may be required if an interaction is suspected. References "Product Information. Polivy (polatuzumab vedotin)." Genentech, South San Francisco, CA.
Professional:MONITOR: Coadministration with inducers of CYP450 3A4 may decrease exposure to unconjugated monomethyl auristatin E (MMAE), the anti-mitotic and cytotoxic component of polatuzumab vedotin. MMAE is a substrate for CYP450 3A4. Concomitant use of polatuzumab vedotin with rifampin, a potent CYP450 3A4 inducer, is predicted to decrease unconjugated MMAE exposure (AUC) by 63% according to the product labeling. No data are available for other, less potent CYP450 3A4 inducers.
MANAGEMENT: The potential for diminished pharmacologic effects of polatuzumab vedotin should be considered during coadministration with CYP450 3A4 inducers. Alternative treatments may be required if an interaction is suspected.
- "Product Information. Polivy (polatuzumab vedotin)." Genentech, South San Francisco, CA.
Generic Name: polatuzumab vedotin
Brand name: Polivy
Synonyms: Polatuzumab vedotin, Polatuzumab Vedotin
Generic Name: somatropin
Brand name: Genotropin, Humatrope, Norditropin FlexPro Pen, Nutropin AQ NuSpin 10, Nutropin AQ Pen 10 Cartridge, Omnitrope, Saizen, Serostim, Zomacton, Zorbtive, Nutropin, Norditropin, Nutropin AQ, Nutropin Depot, Norditropin Cartridge, Genotropin Miniquick, Tev-Tropin, Norditropin Nordiflex Pen, Saizen Click-Easy, Omnitrope Pen 5 Cartridge, HumatroPen, Omnitrope Pen 10 Cartridge, Nutropin AQ Pen 20 Cartridge, Nutropin AQ NuSpin 5, Nutropin AQ NuSpin 20, Saizen Kit
Synonyms: Somatropin
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Polatuzumab Vedotin-piiq-Somatuline Depot
- Polatuzumab Vedotin-piiq-Somavert
- Polatuzumab Vedotin-piiq-Sominex
- Polatuzumab Vedotin-piiq-Somnote
- Polatuzumab Vedotin-piiq-Sonahist
- Polatuzumab Vedotin-piiq-Sonahist DM
- Somatropin, mammalian derived Subcutaneous, Injection-Polio vaccine, inactivated
- Somatropin, mammalian derived Subcutaneous, Injection-Poliovirus Vaccine (Inactivated)
- Somatropin, mammalian derived Subcutaneous, Injection-Poliovirus vaccine, inactivated Injection
- Somatropin, mammalian derived Subcutaneous, Injection-Polivy
- Somatropin, mammalian derived Subcutaneous, Injection-Polmon
- Somatropin, mammalian derived Subcutaneous, Injection-Polocaine